Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics
August 26th 2022
The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.